Friday 6-6-2014 Gilead Sciences (GILD) $GILD opene

Friday 6-6-2014 Gilead Sciences (GILD) $GILD opened at 83.24 hitting the high price of 83.24 and a day low of 81.72 with a total volume of 9,105,200. GILD had a previous close of 82.80 and has been seeing an average volume of 9,896,689.

Overall Average: 40% Buy

Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!

The Repercussions of Medicare's New Hepatitis C Push
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Sun Jun 08, 12:31PM CDT
This week, the Centers for Medicare & Medicaid Services, or CMS, announced a big shift in health policy. CMS intends to cover screening for hepatitis C for members who fall into either of two buckets: those who are considered to be at high risk... (full story)

Final Glance: Biotechnology companies
AP - Fri Jun 06, 5:13PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)

Curis Re-Initiates Dosing for CUDC-427 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 4:10PM CDT
Curis, Inc. (CRIS) announced that it has re-initiated dosing in the single-agent clinical trial on pipeline candidate, CUDC-427. (full story)

Alkermes' Pipeline Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 3:30PM CDT
Alkermes (ALKS) announced the commencement of a 15-month phase II trial on ALKS 3831. (full story)

Jim Cramer: No Joy in Shortville
at The Street - Fri Jun 06, 12:42PM CDT
Shorts take much more homework than longs. (full story)

Midday Glance: Biotechnology companies
AP - Fri Jun 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.: (full story)

Affymetrix, BioDiscovery Launch Cancer Research Software - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 12:10PM CDT
Nexus Copy Number is an advanced discovery tool for interrogating large data sets, specifically tailored for analyzing data generated by Affymetrix Inc.'s (AFFX) genetic analysis platforms. (full story)

Early Glance: Biotechnology companies
AP - Fri Jun 06, 10:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)

Pipeline Progress at GlaxoSmithKline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 10:26AM CDT
GlaxoSmithKline plc (GSK) recently announced that it has initiated a phase III study, LATITUDE-TIMI 60 on cardiovascular candidate losmapimod. (full story)

Celldex Therapeutics (CLDX) Soars: Stock Adds 12.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 8:39AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose nearly 13% on the day. (full story)

Clovis Oncology (CLVS) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 7:51AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session, as its shares rose over 6% on the day. (full story)

MannKind Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 7:00AM CDT
Shares of MannKind (MNKD) hit a 52-week high of $11.11 during the trading session on Jun 5 (full story)

'Mad Money' Lightning Round: I'm Flying With American
at The Street - Fri Jun 06, 5:00AM CDT
Cramer is a believer in Charles Schwab and likes Gilead Sciences and Celgene. (full story)

Vertex Pharmaceuticals Inc.'s Date With Destiny
Brian Orelli, The Motley Fool - Motley Fool - Thu Jun 05, 7:29PM CDT
Vertex Pharmaceuticals said to expect data from two clinical trials testing its cystic fibrosis drugs midyear. It's June. Doesn't get much more midyear than that. The two trials, dubbed Traffic and Transport, are testing VX-809, at two different... (full story)

Jim Cramer's 'Mad Money' Recap: Follow Your Own Investment Path
at The Street - Thu Jun 05, 7:08PM CDT
Investors need to be their own gurus and decide for themselves when it's time to buy and sell. (full story)

Vanda Up on EU News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 6:01PM CDT
Vanda Pharmaceuticals Inc. (VNDA) announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for Hetlioz. (full story)

Roche's Ventana Collaborates with AstraZeneca's MedImmune - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 5:57PM CDT
Roche's (RHHBY) Ventana Medical Systems, Inc. has entered into a collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). (full story)

Positive Phase IIb Data from Jazz Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 5:56PM CDT
Jazz Pharmaceuticals' (JAZZ) JZP-110 met all primary and secondary endpoints in a phase IIb study for the treatment of excessive daytime sleepiness (EDS) in adults suffering from narcolepsy. (full story)

Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 5:26PM CDT
Halozyme Therapeutics, Inc. (HALO) announced that the FDA has removed the clinical hold from PEGPH20 phase II study (Study 202) for stage IV metastatic pancreatic cancer. (full story)